Expertise in
2
conditions

Tanujaa D. Rajasekaran

Oncology
38 Irrawaddy Rd, #05-43, 
Singapore, SG 
Offers Telehealth
Expertise in
2
conditions
38 Irrawaddy Rd, #05-43, 
Singapore, SG 
OverviewLocationsClinical Research

Overview

Tanujaa Rajasekaran practices in Singapore, Singapore. Ms. Rajasekaran is highly rated in 2 conditions, according to our data. Her top areas of expertise are Lung Cancer, EGFR Positive Lung Cancer, Non-Small Cell Lung Cancer (NSCLC), and Prostate Cancer.

Her clinical research consists of co-authoring 20 peer reviewed articles and participating in 1 clinical trial. MediFind looks at clinical research from the past 15 years.

Residency
SingHealth Residency
Specialties
Oncology
Hospital Affiliations
Parkway Hospitals
Languages Spoken
English
Tamil
Gender
Female
Awards
Singapore Health Quality Service Awards in 2019 and 2022

Locations

Mount Elizabeth Novena Hospital
38 Irrawaddy Rd, #05-43, Singapore, 329563, Singapore

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

1 Clinical Trials

A Randomized Phase 3 Multicenter Open-Label Study to Compare the Efficacy of TAK-788 as First-Line Treatment Versus Platinum-Based Chemotherapy in Patients With Non-Small Cell Lung Cancer With EGFR Exon 20 Insertion Mutations
A Randomized Phase 3 Multicenter Open-Label Study to Compare the Efficacy of TAK-788 as First-Line Treatment Versus Platinum-Based Chemotherapy in Patients With Non-Small Cell Lung Cancer With EGFR Exon 20 Insertion Mutations
Enrollment Status: Active_not_recruiting
Publish Date: April 22, 2025
Intervention Type: Drug
Study Drugs: TAK-788, Pemetrexed, Cisplatin, Carboplatin
Study Phase: Phase 3

20 Total Publications

Detection of circulating tumor DNA with ultradeep sequencing of plasma cell-free DNA for monitoring minimal residual disease and early detection of recurrence in early-stage lung cancer.
Detection of circulating tumor DNA with ultradeep sequencing of plasma cell-free DNA for monitoring minimal residual disease and early detection of recurrence in early-stage lung cancer.
Journal: Cancer
Published: September 28, 2023

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Ms. Rajasekaran's expertise for a condition
ConditionClose
      Want to save this expert for later?
      Sign Up
      Not sure about your diagnosis?
      Check Your Symptoms
       
       
       
       
      Learn about our expert tiers
      Learn More
      Are you the provider on this profile?
      Claim Profile